ReviewAmerican journal of translational research2023

Can proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis.

Zijia Wu et al.PubMed ↗Full text ↗

No numbers read from the abstract.